Background
Neuromyelitis optica‐optic neuritis (NMO‐ON) patients are routinely treated with intravenous methylprednisolone (IVMP). For the patients nonresponsive to IVMP, more effective but aggressive therapy of plasma exchange (PE) should be employed instead of IVMP in the first line.
Purpose
To assess the visual outcomes of NMO‐ON patients after IVMP by radiomics analysis of whole brain diffusion tensor imaging (DTI) data.
Study Type
Retrospective.
Population
In all, 57 NMO‐ON patients receiving IVMP therapy for 3 days.
Field Strength/Sequence
3.0T; DTI images acquired by a single‐shot echo planar image sequence; T1 images acquired by 3D fast spoiled gradient echo (3D‐FSPGR) MRI.
Assessment
In all, 200 DTI measures were extracted from the DTI data and employed as features to construct a radiomics assessment model for visual outcomes of NMO‐ON patients after IVMP. The assessment performance was evaluated by area under the receiver operating characteristic curve (AUC), classification accuracy (ACC), sensitivity, specificity, and positive and negative predicted values (PPV and NPV). The selected DTI measures would reveal the white matter impairments related to visual recovery of NMO‐ON patients.
Statistical Tests
The relationship between the selected DTI measures and the clinical visual characteristics were investigated by Pearson correlation, Spearman's rank correlation, and one‐way analysis of variance analysis.
Results
The radiomics model obtained an ACC of 73.68% (P = 0.002), AUC of 0.7931, sensitivity of 0.6207, specificity of 0.8571, PPV of 0.8182, and NPV of 0.6857 in assessing visual outcomes of the NMO‐ON patients after IVMP treatment. The selected DTI measures revealed white matter impairments related to the visual outcomes in the white matter tracts of vision‐relevant regions, motor‐related regions, and corpus callosum. The white matter impairments were found significantly correlated with the disease duration and the length of lesions in the optic nerve.
Data Conclusion
Radiomics analysis of DTI data has great potential in assessing visual outcomes of NMO‐ON patients after IVMP therapy.
Level of Evidence: 2
Technical Efficacy: Stage 4
J. Magn. Reson. Imaging 2019;49:1365–1373.